Maze Therapeutics, Inc. (MAZE) stock

MAZENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30

$34.33−1.76 (-4.88%)

Close on Nov 13, 2026Market cap $1.91BP/E –Yield –

Maze Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Maze Therapeutics's total debt was $39.12M at Sep 30, 2026.

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	$39.12M	–
Q2 FY2026	Jun 30, 2026	$38.96M	–
Q1 FY2026	Mar 31, 2026	$38.83M	–

See a number that looks wrong?